Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
In a Diabetes Care randomized trial, Glucagon antagonism enhances the therapeutic effects of SGLT2 inhibition in type 1 diabetes. Key reported results included Average glucose and percent time with glucose in range (70-180 mg/dL) improved with combination therapy versus Baseline and SGLT2...
In a J Clin Endocrinol Metab randomized trial, A higher cumulative HbA1c was significantly associated with a higher risk of retinopathy. Key reported results included No significant difference was found in the cumulative incidence of clinically diagnosed DR between the original intervention (N =...
In SURPASS-PEDS, weekly tirzepatide lowered HbA1c by 2.28 points versus placebo at 30 weeks and also reduced BMI in youth-onset type 2 diabetes.
In gestational diabetes requiring medication, metformin-first oral therapy with glyburide rescue did not prove noninferior to insulin for preventing large-for-gestational-age birth.
In overweight or obese adults with early type 2 diabetes, dapagliflozin added to calorie restriction increased 12-month remission from 28% to 44%.
In insulin-treated type 2 diabetes, automated insulin delivery reduced HbA1c by an adjusted 0.6 percentage points and increased time in range by 14 points versus CGM with usual insulin delivery.
In CKD with type 2 diabetes and albuminuria, simultaneous finerenone plus empagliflozin reduced UACR more than either treatment alone at 180 days, without unexpected safety findings.
In REDEFINE 2, CagriSema reduced weight by 13.7% versus 3.4% with placebo at 68 weeks, and 73.5% achieved HbA1c <=6.5% in adults with type 2 diabetes.
In high-risk type 2 diabetes, once-daily oral semaglutide 14 mg cut major adverse cardiovascular events versus placebo in the SOUL trial, with no kidney benefit shown. PICO summary and expert commentary.
A single-centre Egyptian RCT found the Diabetes Conversation Map programme improved diabetes knowledge, self-management, and self-efficacy questionnaire scores versus standard education (p < 0.001), with no clinical endpoints reported. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
